Non-invasive delivery of polypeptides through the blood-brain barrier

• US 20030083299A1
• Filed: 07/02/2002
• Published: 05/01/2003
• Est. Priority Date: 11/04/2000
• Status: Abandoned Application

• Current Assignee: Ian A. Ferguson
• Original Assignee: Ian A. Ferguson
• Inventors: Ferguson, Ian A.
• Application Number:
  US10/188,184
• Publication Number:
  US 20030083299A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0058 Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
• CPC Class Codes: A61K 48/0075 characterised by an aspect of the delivery route, e.g. oral, subcutaneous
• CPC Class Codes: C07K 16/005 constructed by phage libraries
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/16643 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2740/15043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2810/851 from growth factors; from growth regulators
• CPC Class Codes: C12N 2810/859 from immunoglobulins
• CPC Class Codes: C12N 2830/00 Vector systems having a special element relevant for transcription

Abstract

A treatment method and genetic vectors are disclosed for non-invasive delivery of polypeptides through the blood brain barrier (BBB), to treat brain or spinal tissue. A genetic vector is used to transfect one or more neurons which “straddle” the BBB, such as sensory neurons, nocioceptive neurons, or lower motor neurons; this is done by administering the vector in a manner that causes it to contact neuronal projections that extend outside the BBB. Once inside a peripheral projection that belongs to a BBB-straddling neuron, the vectors (or some portion thereof) will be transported to the main cell body of the neuron, through a process called retrograde transport. Inside the main cell body, at least one gene carried by the genetic vector will be expressed, to form polypeptides. Some of these polypeptides (which can include leader sequences that will promote anterograde transport and secretion by BBB-straddling neurons) will be transported by the neurons to secretion sites inside the BBB. The polypeptides will be secreted by transfected neurons at locations inside the BBB, and will then contact and exert their effects upon secondary “target” neurons located entirely within the BBB. By using this system, polypeptides that stimulate nerve growth or activity can be used to treat neurodegenerative diseases, impaired limbs in stroke victims, etc., and polypeptides that suppress neuronal activity can be used to treat unwanted excessive neuronal activity, such as neuropathic pain. This approach also provides new methods for delivering endocrine and paracrine polypeptides into the CNS, thereby allowing improved medical and reproductive treatments in humans, and improved ability to modulate growth, maturation, reproduction, or other endocrine-related functions among livestock, endangered species, and other animals.

Claims

1. A method for delivering neuroactive polypeptide molecules through a blood-brain barrier in a higher animal, comprising the steps of:

a. creating a genetic vector which carries at least one gene which encodes a neuroactive polypeptide, and which is constructed in a manner which will enable the genetic vector to transfect at least one class of accessible neurons which straddle the blood-brain barrier, each such accessible neuron having at least one peripheral projection that is accessible to compounds that have not penetrated the animal'"'"'s blood-brain barrier, if said genetic vector is administered to such higher animal by means which cause direct contact between at least one copy of the genetic vector and at least one such peripheral projection, wherein the gene which encodes the neuroactive polypeptide is capable of expressing copies of the neuroactive polypeptide within such accessible neurons after such accessible neurons have been transfected by said genetic vector; and

,

b. administering the genetic vector to the higher animal in a location and manner which ensure that;

(i) at least one copy of the genetic vector contacts and transfects at least one such accessible neuron; and

(ii) at least one such accessible neuron expresses the neuroactive polypeptide encoded by the gene and subsequently secretes the neuroactive polypeptide into central nervous system tissue which is protected by the blood-brain barrier.

2. The method of claim 1, wherein the accessible neurons which straddle the blood-brain barrier are sensory neurons.

3. The method of claim 2, wherein the sensory neurons are olfactory receptor neurons.

4. The method of claim 2, wherein the sensory neurons are nocioceptive neurons.

5. The method of claim 1, wherein the accessible neurons which straddle the blood-brain barrier are motor neurons.

6. The method of claim 5, wherein the motor neurons are spinal motor neurons.

7. The method of claim 5, wherein the motor neurons are motor neurons of the hypoglossal nucleus.

8. The method of claim 1, wherein the accessible neurons which straddle the blood-brain barrier are pre-ganglionic neurons of the parasympathetic nervous system.

9. The method of claim 1, wherein the accessible neurons which straddle the blood-brain barrier are pre-ganglionic neurons of the sympathetic nervous system.

10. The method of claim 1, wherein the neuroactive polypeptide is selected from the group consisting of neurotrophic factors, endocrine factors, growth factors, paracrine factors, hypothalamic releasing factors, neurotransmitter polypeptides, antibodies and antibody fragments which bind to neurotrophic factors, antibodies and antibody fragments which bind to neurotrophic factor receptors, polypeptide antagonists, agonists for a receptor expressed by a CNS cell, and polypeptides involved in lysosomal storage disease.

11. The method of claim 1, wherein the genetic vector contains cell transfection components that include at least a portion of a viral capsid active on a mammalian cell.

12. The method of claim 1, wherein the genetic vector comprises a cationic liposome or other gene transfection lipid.

13. The method of claim 1, wherein the genetic vector comprises a ligand which binds in a specific manner to at least one type of endocytotic receptor on the accessible neurons.

14. The method of claim 13, wherein the ligand has been identified through selection steps which include:

(a) subjecting a multiplicity of neurons of a selected type to contact by a phagemid or phage display library, each phage in the library carrying a candidate DNA sequence and having on an exposed phage surface a polypeptide encoded by the candidate DNA sequence, and the phage display library consisting of multiple phage particles with multiple candidate DNA sequences and corresponding polypeptides exposed on the phage surfaces;

(b) selecting at least one clonal phage line from the phage display library, wherein the selected clonal phage line was transported into neurons of the selected type.

15. The method of claim 1, wherein the genetic vector comprises a macromolecule that has been shown to promote transneuronal passage of associated genetic material out of a selected type of accessible neuron which straddles the blood-brain barrier and into at least one type of neuron which is positioned entirely within central nervous system tissue and protected by the blood-brain barrier of an animal.

16. The method of claim 1, wherein the genetic vector encodes a chimeric polypeptide comprising:

a. a leader sequence which enables or promotes anterograde transport of the chimeric polypeptide within a neuron that expresses the chimeric polypeptide; and

,

b. a neuroactive sequence which can create a therapeutic benefit by reacting with cells located wholly within CNS tissue that is protected by the blood-brain barrier, after secretion within the blood-brain barrier by an accessible neuron which straddles the blood-brain barrier.

17. The method of claim 1, wherein the genetic vector encodes a chimeric polypeptide comprising:

a. a leader sequence which enables or promotes secretion of the chimeric polypeptide at neuronal termini located within CNS tissue that is protected by the blood-brain barrier of an animal; and

,

b. a neuroactive sequence which can create a therapeutic benefit by reacting with cells located wholly within CNS tissue that is protected by the blood-brain barrier, after secretion within the blood-brain barrier by an accessible neuron which straddles the blood-brain barrier.

18. A method for delivering neuroactive polypeptide molecules through a blood-brain barrier in a higher animal, comprising the step of administering to the higher animal a genetic vector which carries at least one gene which encodes a neuroactive polypeptide,

wherein said genetic vector has been constructed in a manner which enables the genetic vector to transfect at least one class of accessible neuron which straddles the blood-brain barrier, if administered to such higher animal in a location and manner which causes direct contact between the genetic vector and such accessible neurons which straddle the blood-brain barrier,

and wherein said genetic vector is administered to such higher animal in a location and manner which ensures that:

(i) at least one copy of the genetic vector contacts and transfects at least one such accessible neuron;

(ii) at least one transfected accessible neuron expresses copies of at least one neuroactive polypeptide encoded by at least one gene carried by said genetic vector; and

, (iii) at least one transfected accessible neuron secretes copies of at least one such neuroactive polypeptide, at a location within central nervous system tissue protected by the blood-brain barrier.

19. The method of claim 18, wherein the genetic vector has been designed to transfect sensory neurons.

20. The method of claim 18, wherein the genetic vector has been designed to transfect motor neurons.

21. The method of claim 18, wherein the genetic vector has been designed to transfect pre-ganglionic neurons of the parasympathetic nervous system.

22. The method of claim 18, wherein the genetic vector has been designed to transfect pre-ganglionic neurons of the sympathetic nervous system.

23. The method of claim 18, wherein the neuroactive polypeptide is selected from the group consisting of neurotrophic factors, endocrine factors, growth factors, paracrine factors, hypothalamic release factors, neurotransmitter polypeptides, antibodies and antibody fragments which bind to neurotrophic factors, antibodies and antibody fragments which bind to neurotrophic factor receptors, polypeptide antagonists, agonists for a receptor expressed by a CNS cell, and polypeptides involved in lysosomal storage disease.

24. The method of claim 18, wherein the genetic vector contains cell transfection components that include at least a portion of a viral capsid active on a mammalian cell.

25. The method of claim 18, wherein the genetic vector comprises a cationic liposome or other gene transfection lipid.

26. The method of claim 18, wherein the genetic vector comprises a ligand which binds in a specific manner to at least one type of endocytotic receptor on the accessible neurons.

27. The method of claim 18, wherein the genetic vector comprises a macromolecule that has been shown to promote transneuronal passage of associated genetic material out of a selected type of accessible neuron which straddles the blood-brain barrier and into at least one type of neuron which is positioned entirely within central nervous system tissue and protected by the blood-brain barrier of an animal.

28. The method of claim 18, wherein the genetic vector encodes a chimeric polypeptide comprising:

a. a leader sequence which enables or promotes anterograde transport of the chimeric polypeptide within a neuron that expresses the chimeric polypeptide; and

,

b. a neuroactive sequence which can create a therapeutic benefit by reacting with cells located wholly within CNS tissue that is protected by the blood-brain barrier, after secretion within the blood-brain barrier by an accessible neuron which straddles the blood-brain barrier.

29. The method of claim 18, wherein the genetic vector encodes a chimeric polypeptide comprising:

a. a leader sequence which enables or promotes secretion of the chimeric polypeptide at neuronal termini located within CNS tissue that is protected by the blood-brain barrier of an animal; and

,

b. a neuroactive sequence which can create a therapeutic benefit by reacting with cells located wholly within CNS tissue that is protected by the blood-brain barrier, after secretion within the blood-brain barrier by an accessible neuron which straddles the blood-brain barrier.

30. A genetic vector designed to initiate and capable of initiating a neuronal process that will non-invasively deliver neuroactive polypeptide molecules into central nervous system tissue protected by a blood-brain barrier in a higher animal, said genetic vector comprising cell transfection components and associated genetic material, which have been assembled into a genetic vector which is suited for and capable of transfecting at least one type of accessible neuron which straddles the blood-brain barrier and has at least one peripheral projection that is accessible to genetic vectors that have not penetrated an animal'"'"'s blood-brain barrier,

wherein:

a. the cell transfection components are selected to cause the genetic vector to (i) bind to the selected type of accessible neuron, and (ii) insert associated genetic material carried by the genetic vector into the accessible neurons; and

,

b. the associated genetic material contains at least one gene which encodes a neuroactive polypeptide, wherein said gene has a gene promoter that causes the gene to be expressed, inside transfected accessible neurons, into said neuroactive polypeptide or a precursor thereof, and wherein copies of the neuroactive polypeptide or precursor thereof have been shown to be (i) transported, within transfected accessible neurons, to neuronal secretion locations in central nervous system tissue that is protected by the blood-brain barrier of the animal, and (ii) secreted by transfected accessible neurons at such neuronal secretion locations, in central nervous system tissue that is protected by the blood-brain barrier of the animal.

31. The genetic vector of claim 30, which has been proven in in vivo mammalian tests to be fully capable of initiating a neuronal process that will non-invasively deliver neuroactive polypeptide molecules, encoded by the genetic vector and expressed within transfected accessible neurons, into central nervous system tissue protected by a blood-brain barrier in at least one mammalian species.

32. The genetic vector of claim 30, which has been proven in human clinical trials to be fully capable of initiating a neuronal process that will non-invasively deliver neuroactive polypeptide molecules, encoded by the genetic vector and expressed within transfected accessible neurons, into central nervous system tissue protected by a blood-brain barrier in treated human patients.

33. The genetic vector of claim 30, which is designed to transfect at least one type of sensory neuron.

34. The genetic vector of claim 33, which is designed to transfect olfactory receptor neurons.

35. The genetic vector of claim 33, which is designed to transfect nocioceptive neurons.

36. The genetic vector of claim 30, which is designed to transfect at least one type of motor neuron.

37. The genetic vector of claim 30, which is designed to transfect at least one type of pre-ganglionic neuron belonging to a sympathetic or parasympathetic nervous system of a higher animal.

38. The genetic vector of claim 30, wherein the gene encodes a neuroactive polypeptide selected from the group consisting of neurotrophic factors, endocrine factors, growth factors, paracrine factors, hypothalamic release factors, neurotransmitter polypeptides, antibodies and antibody fragments which bind to neurotrophic factors, antibodies and antibody fragments which bind to neurotrophic factor receptors, polypeptide antagonists, agonists for a receptor expressed by a CNS cell, and polypeptides involved in lysosomal storage disease.

39. The genetic vector of claim 30, wherein the cell transfection components comprise at least a portion of a mammalian viral capsid.

40. The genetic vector of claim 30, wherein the cell transfection components comprise a cationic liposome.

41. The genetic vector of claim 30, wherein the cell transfection components comprise a ligand which binds in a specific manner to at least one type of endocytotic receptor on the accessible neurons.

42. The genetic vector of claim 41, wherein the ligand has been identified through selection steps which include:

(a) subjecting a multiplicity of neurons of a selected type to contact by a phagemid or phage display library, each phage in the library carrying a candidate DNA sequence and having on an exposed phage surface a polypeptide encoded by the candidate DNA sequence, and the phage display library consisting of multiple phage particles with multiple candidate DNA sequences and corresponding polypeptides exposed on the phage surfaces;

(b) selecting at least one clonal phage line from the phage display library, wherein the selected clonal phage line was efficiently transported into neurons of the selected type.

43. The genetic vector of claim 30, wherein the cell transfection components comprise a polypeptide that has been shown to promote transneuronal passage of associated genetic material out of a selected type of accessible neuron which straddles the blood-brain barrier and into at least one type of neuron which is positioned entirely within central nervous system tissue and protected by the blood-brain barrier of an animal.

44. The genetic vector of claim 30, which encodes a chimeric polypeptide comprising:

a. a leader sequence which enables or promotes anterograde transport of the chimeric polypeptide within a neuron that expresses the chimeric polypeptide; and

,

b. a neuroactive sequence which can create a therapeutic benefit by reacting with cells located wholly within CNS tissue that is protected by the blood-brain barrier, after secretion within the blood-brain barrier by an accessible neuron which straddles the blood-brain barrier.

45. The genetic vector of claim 30, which encodes a chimeric polypeptide comprising:

a. a leader sequence which enables or promotes secretion of the chimeric polypeptide at neuronal termini located within CNS tissue that is protected by the blood-brain barrier of an animal; and

,

b. a neuroactive sequence which can create a therapeutic benefit by reacting with cells located wholly within CNS tissue that is protected by the blood-brain barrier, after secretion within the blood-brain barrier by an accessible neuron which straddles the blood-brain barrier.

46. A genetic vector designed to initiate and capable of initiating a neuronal process that will non-invasively deliver neuroactive polypeptide molecules into central nervous system tissue protected by a blood-brain barrier in a higher animal, wherein the genetic vector encodes a chimeric polypeptide comprising:

a. a leader sequence which enables or promotes at least one activity elected from the group consisting of;

(i) anterograde transport of the chimeric polypeptide within a neuron that expresses the chimeric polypeptide; and

,

(ii) secretion of the chimeric polypeptide at neuronal termini located within CNS tissue that is protected by the blood-brain barrier of an animal; and

,

b. a neuroactive sequence which can create a therapeutic benefit by reacting with cells located wholly within CNS tissue that is protected by the blood-brain barrier, after secretion within the blood-brain barrier by a neuron which straddles the blood-brain barrier.

47. The genetic vector of claim 46, wherein the neuroactive sequence of the polypeptide is selected from the group consisting of neurotrophic factors, endocrine factors, growth factors, paracrine factors, hypothalamic release factors, neurotransmitter polypeptides, antibodies and antibody fragments which bind to neurotrophic factors, antibodies and antibody fragments which bind to neurotrophic factor receptors, polypeptide antagonists, agonists for a receptor expressed by a CNS cell, and polypeptides involved in lysosomal storage disease.